Zai Lab Announces Promotion of Harald Reinhart, M.D. to
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused,...
Source: globenewswire.com
📰 Zai Lab News
Page 70 - Zai Lab News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Zai Lab. Real-time updates on events, politics, business and more.
China NMPA Approves NUZYRA® as a Category 1 Innovative Drug
NUZYRA demonstrated efficacy against common pathogens in three Phase 3 studies, including pathogens resistant to other antibiotic classes as a potential...
Source: globenewswire.com
Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases
22.12.2021 - SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) - Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the promotion of ... Seite 1
Bayer Corp Head Of Clinical Development Zai Lab Clinical Development Senior Vice President Medical Affairs
Source: wallstreet-online.de
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
Argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
Source: dutchnews.nl
Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
18.12.2021 - VYVGART is the first and only FDA-approved neonatal Fc receptor blocker 68% of anti-acetylcholine receptor (AChR) antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis - Activities of Daily Living ... Seite 1
Source: wallstreet-online.de
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
BREDA, Netherlands--(BUSINESS WIRE)--Dec 17, 2021--
Source: kulr8.com
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis | Antibodies
Argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
Source: pipelinereview.com
Ambuja Cement Foundation and Sir Mathuradas Vissanji Education Trust encourage machine operations and manufacturing training at Skill & Entrepreneurship Development Institute
Thanks to the Sir Mathuradas Vissanji Education Trust, Ambuja Cement Foundation (ACF) has been able to install a CNC plasma cutting machine at its Skill & Entrepreneurship Development Institute (SEDI) in Ambujanagar and Chandrapur to encourage girls’ participation in machine operations and manufacturing.
Pearl Tiwari Mathuradas Vissanji Arati Vissanji Skill Entrepreneurship Development Institute Sir Mathuradas Vissanji Education Sir Mathuradas Vissanji
Source: worldcement.com
argenx SE: argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
VYVGART is the first-and-only FDA-approved neonatal Fc receptor blocker 68% of anti-acetylcholine receptor (AChR) antibody positive gMG patients treated with VYVGART were responders (n=44/65)
Source: finanznachrichten.de